CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 588 enrolled
Drug / intervention
doxorubicin hydrochloride +4 moredrug
Likely dose
Doxorubicin (IV) and ifosfamide (IV) with doses determined by treatment regimen; 3-dimensional conformal radiotherapy and surgery also usedAI-extracted
Key inclusion· 7
  • Newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma (STS) confirmed by central pathology review, either metastatic or non-metastatic
  • Meets criteria for intermediate or malignant STS histology (adipocytic, fibroblastic/myofibroblastic, fibrohistiocytic, smooth muscle, vascular, chondro-osseous, tumors of uncertain differentiation, or malignant peripheral nerve sheath tumor)
  • Gross resection of primary tumor completed ≤42 days prior to enrollment, with exceptions for high-grade tumors >5 cm, tumors not grossly resectable without unacceptable morbidity, or metastatic high-grade disease
  • Lansky performance status 50-100% (age ≤16 years) OR Karnofsky 50-100% (age >16 years)
Key exclusion· 5
  • Tumors arising in bone
  • Patients with tumor recurrence after gross total resection
  • Prior anthracycline (doxorubicin or daunorubicin) or ifosfamide chemotherapy for patients on arms C or D
  • Prior radiotherapy to tumor-involved sites

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00346164
NCT00346164Phase 3Completed

Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age

Children's Oncology Group·interventional·Posted Jun 29, 2006·Updated Apr 28, 2022

In Brief

A Phase 3 clinical trial evaluating doxorubicin hydrochloride, clinical observation, and 3 other interventions for Adult Alveolar Soft-part Sarcoma and 28 related conditions. Completed, enrolled 588 participants across 187 sites in 5 countries.

Detailed Summary

This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma. In the study, patients are assigned to receive surgery +/- radiotherapy +/- chemotherapy depending on their risk of recurrence. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.

Study Details

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 29, 2006
Enrollment StartFeb 5, 2007
Primary CompletionSep 5, 2014
Study CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 20.0 years ago

Interventions

doxorubicin hydrochloridedrug

Given IV

clinical observationother

Patients undergo observation

therapeutic conventional surgeryprocedure

Patients undergo surgery

3-dimensional conformal radiation therapyradiation

Patients undergo radiotherapy

ifosfamidedrug

Given IV